Abstract
The Dutch on-the-road driving test is a standardized test, conducted on a public highway in actual traffic. Participants are instructed to drive for 100-km, while maintaining a steady lateral position and constant speed (95 km/h). Standard Deviation of Lateral Position (SDLP) is the primary outcome measure of the test. This review summarizes the results of 30 years of Dutch on-the-road driving research applying this test. Many central nervous system (CNS)-drugs show dose-dependent impairment on the driving test, expressed in significantly elevated SDLP values relative to placebo. This review discusses several determinants of drug-related driving impairment, including those related to the drug, its use, driver demographics, and the environment. Implications for study design, and limitations of the current methodology are discussed, as well as future challenges to improve the methodology. Overall, the on-the-road driving test has proven to be a reliable and sensitive test to assess the potential effects of CNS drugs on driving ability.
Keywords: Driving, safety, SDLP, on-the-road test, CNS-drugs, anxiolytics, hypnotics, triazolam, flurazepam, benzodiazepines, PLACEBO, sleepiness, methylphenidate, neurobehavioral, tolerance
Current Psychopharmacology
Title: Thirty Years of Dutch Drugs and Driving Research: Strengths and Limitations of the On-The-Road Highway Driving Test and Future Challenges
Volume: 1
Author(s): Joris C. Verster and Thomas Roth
Affiliation:
Keywords: Driving, safety, SDLP, on-the-road test, CNS-drugs, anxiolytics, hypnotics, triazolam, flurazepam, benzodiazepines, PLACEBO, sleepiness, methylphenidate, neurobehavioral, tolerance
Abstract: The Dutch on-the-road driving test is a standardized test, conducted on a public highway in actual traffic. Participants are instructed to drive for 100-km, while maintaining a steady lateral position and constant speed (95 km/h). Standard Deviation of Lateral Position (SDLP) is the primary outcome measure of the test. This review summarizes the results of 30 years of Dutch on-the-road driving research applying this test. Many central nervous system (CNS)-drugs show dose-dependent impairment on the driving test, expressed in significantly elevated SDLP values relative to placebo. This review discusses several determinants of drug-related driving impairment, including those related to the drug, its use, driver demographics, and the environment. Implications for study design, and limitations of the current methodology are discussed, as well as future challenges to improve the methodology. Overall, the on-the-road driving test has proven to be a reliable and sensitive test to assess the potential effects of CNS drugs on driving ability.
Export Options
About this article
Cite this article as:
C. Verster Joris and Roth Thomas, Thirty Years of Dutch Drugs and Driving Research: Strengths and Limitations of the On-The-Road Highway Driving Test and Future Challenges, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010097
DOI https://dx.doi.org/10.2174/2211556011201010097 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia
Current Drug Targets - CNS & Neurological Disorders Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Current Neuropharmacology Inducible Nitric Oxide Synthase Inhibition by Mycophenolic Acid
Mini-Reviews in Medicinal Chemistry Polymorphisms at the LDLR Locus may be Associated with Ischemic Cerebrovascular Disease Independent of Lipid Profile
Current Neurovascular Research Post-stroke Engagement-sensitive Balance Rehabilitation Under An Adaptive Multi-level Electrotherapy: Clinical Hypothesis and Computational Framework
Neuroscience and Biomedical Engineering (Discontinued) Editorial [Hot Topic: The Pros of Not Being Competitive (Allosteric Modulation of GPCRs) (Guest Editors: Vincent Mutel and Bernhard Bettler)]
Current Neuropharmacology New Perspectives for Melanoma Immunotherapy: Role of IL-12
Current Molecular Medicine Meet Our Managing Editor:
Neuroscience and Biomedical Engineering (Discontinued) Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications
Current Molecular Medicine Synthesis, Characterization and Cholinesterase Inhibition Studies of New Arylidene Aminothiazolylethanone Derivatives
Medicinal Chemistry Epigenetics and Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Activity of Drugs and Components of Natural Origin in the Severe Myoclonic Epilepsy of Infancy (Dravet Syndrome)
Central Nervous System Agents in Medicinal Chemistry Medical Treatment of Gastrointestinal Stromal Tumors: State of the Art and Future Perspectives
Reviews on Recent Clinical Trials Hemodialysis Membranes for Acute and Chronic Renal Insufficiency
Current Neurovascular Research Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Factors Impacting the Current Trends in the Use of Outpatient Psychiatric Treatment Among Diverse Ethnic Groups
Current Psychiatry Reviews Adenosine A1 Receptor: Analysis of the Potential Therapeutic Effects Obtained by its Activation in the Central Nervous System
Current Medicinal Chemistry A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research Management of Acute Coronary Syndromes in Patients with Renal Insufficiency
Current Cardiology Reviews